Major histocompatibility complex-mismatched allogeneic bone marrow transplantation using perforin and/or Fas ligand double-defective CD4+ donor T cells: Involvement of cytotoxic function by donor lymphocytes prior to graft-versus-host disease pathogenesis

Blood

Volumn 98, Issue 2, 2001, Pages 390-397

  Jiang, Zhe ^a   Podack, Eckhard ^a   Levy, Robert B ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; FAS LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 3; PERFORIN;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EFFECTOR CELL; GRAFT VERSUS HOST REACTION; HOST RESISTANCE; LYMPH NODE; MAJOR HISTOCOMPATIBILITY COMPLEX; MORTALITY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SPLEEN; WEIGHT REDUCTION; WHOLE BODY RADIATION;

EID: 0035880242     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.2.390     Document Type: Article

References (31)

1. Deeg HJ, Storb R. Graft-versus-host disease: pathophysiological and clinical aspects. Ann Rev Med. 1984;35:11-24.
2. Sale G, Buckner CD. Pathology of bone marrow in transplant recipients. Hematol Oncol Clin North Am. 1988;2:735-756.
3. Baker MB, Altman NH, Podack ER, et al. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med. 1996;183:2645-2656.
4. Levy RB, Baker M, Podack ER. Perforin-deficient T cells can induce acute GVHD following transplantation of MHC matched or MHC disparate allogeneic bone marrow. Ann N Y Acad Sci. 1995;770:366-367.
5. Baker MB, Riley RL, Podack ER, et al. Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function. Proc Natl Acad Sci U S A. 1997;94:1366-1371.
6. Graubert TA, Russell JH, Ley T. The role of granzyme B in murine models of acute graft-versus-host disease and graft rejection. Blood. 1996;87:1232-1237.
7. + T cells each can utilize a perforin-dependent pathway to mediate lethal graft-versus-host disease in major histocompatibility complex-disparate recipients. Transplantation. 1997;64:571-576.
8. Graubert TA, Dispersio J, Russell J, et al. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J Clin Invest. 1997;100:904-911.
9. Hattori K, Hirano T, Miyajima H, et al. Differential effects of anti-fas ligand and anti-tumor necrosis factor antibodies on acute graft-versus-host disease pathologies. Blood. 1998;91:4051-4055.
10. Braun YM, Lowin B, French L, et al. Cytotoxic T cells deficient in both functional Fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med. 1996;183:657-661.
11. Martin P, Akatsuka Y, Hahne M, et al. Involvement of donor T-cell cytotoxic effector mechanisms in preventing allogeneic marrow graft rejection. Blood. 1998;92:2177-2181.
12. Jiang Z, Podack ER, Levy RB. Donor T cells which cannot mediate perforin-dependent and FasL-dependent cytotoxicity can effect graft vs. host reactivity following allogeneic bone marrow transplantation. Periodicum Biologorum. 1998;100:477-481.
13. Spielman J, Lee R, Podack ER. Perforin/Fas-ligand double deficiency is associated with macrophage expansion and severe pancreatitis. J Immunol. 1998;161:7063-7070.
14. Kagi D, Vignaux F, Ledermann B, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science. 1994;265:528-530.
15. Jones M, Komatsu M, Levy RB. Cytotoxically impaired transplant recipients can efficiently resist major histocompatibility complex-matched bone marrow allografts. Biol Blood Marrow Transplant. 2000;6:456-464.
16. Cooke K, Kobzik L, Martin TR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation, I: the roles of minor H antigens and endotoxin. Blood. 1996;8:3230-3239.
17. Korngold R, Sprent J. Surface markers of T cells causing lethal graft-vs-host disease to class I vs class II H-2 differences. J Immunol. 1985;135:3004-3010.
18. Sprent J, Schaefer M, Lo D, et al. Properties of purified T cell subsets, II: in vivo responses to class I vs. class II H-2 differences. J Exp Med. 1986;163:998-1011.
19. Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host disease. Blood. 1992;80:2964-2968.
20. Ferrara JLM, Levy RB, Chao NJ. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant. 1999;5:347-356.
21. van Bekkum DW, De Vries JJ. Radiation Chimaeras. London, England: Logos; 1967.
22. Korngold R, Sprent J. Lethal graft-versus-host disease following bone marrow transplantation across minor histocompatibility barriers in mice: prevention by removing mature T cells from marrow. J Exp Med. 1978;148:1687-1698.
23. Kernan NA, Collins NH, Juliano L, et al. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood. 1986;68:770-773.
24. Via CS, Nguyen P, Shustov A, et al. A major role for the Fas pathway in acute graft-versus-host disease. J Immunol. 1996;157:5387-5393.
25. Aizawa S, Sado T, Kamisaku H, et al. Cellular basis of the immunohematologic defects observed in short-term semiallogeneic B6C3F1-C3H chimeras: evidence for host-versus-graft reaction initiated by radioresistant T cells. Cell Immunol. 1980;56:47-57.
26. Dennert G, Anderson CG, Warner J. T killer cells play a role in allogeneic bone marrow graft rejection but not in hybrid resistance. J Immunol. 1985;135:3729-3734.
27. Murphy WJ, Kumar V, Bennett M. Acute rejection of murine bone marrow allografts by natural killer cells and T cells: differences in kinetics and target antigens recognized. J Exp Med. 1987;166:1499-1509.
28. Kiessling R, Hochman PS, Haller O, et al. Evidence for a similar or common mechanism for natural killer cell activity and resistance to hemopoietic grafts. Eur J Immunol. 1977;7:655-663.
29. Warner JF, Dennert G. Effects of a cloned cell line with NK activity on bone marrow transplants, tumour development and metastasis in vivo. Nature. 1982;300:31-34.
30. Murphy WJ, Kumar V, Bennett M. Rejection of bone marrow allografts by mice with severe combined immune deficiency (SCID): evidence that natural killer cells can mediate the specificity of marrow graft rejection. J Exp Med. 1987;165:1212-1217.
31. Martin PJ. Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans. J Exp Med. 1993;178:703-712.